Glutamine is the primary fuel for cells that line the intestine, before glucose. This physiological basis is why it is discussed for intestinal barrier, irritable bowel, and what the internet calls leaky gut. The basis is solid; what is less solid is how promises are drawn from it.
This guide reports what trials have measured: a meta-analysis of ten studies on intestinal permeability, a randomized trial published in Gut in very specific patients, what the term "leaky gut" actually covers, data in athletes, and the safety limit set by a trial in the New England Journal of Medicine. Our guide to glutamine and recovery addresses muscle.
Permeability. A meta-analysis of ten trials and 352 patients finds no overall effect of glutamine on intestinal permeability; an effect appears in a subgroup above 30 g per day for less than two weeks. Post-infectious irritable bowel. A trial in Gut, 5 g three times daily for eight weeks in patients with measured hyperpermeability: 79.6% responders versus 5.8% under placebo, normalized permeability, no serious adverse effects. A narrow and clear profile.
Leaky gut is a measurable quantity, not an independent diagnosis. The athlete : the reference review finds no solid support for immunity. Safety : up to 30 g per day well tolerated in healthy adults; in intensive care, the REDOXS trial showed excess mortality at high doses, hence the rule: serious illness, doctor first.
Why glutamine and the intestine
Glutamine is the most abundant amino acid in the blood and muscles, and the body produces it itself. The enterocytes, the cells that line the intestine and renew themselves every few days, use it as their primary fuel, before glucose. In situations of metabolic stress, infection, surgery, burns, or very prolonged exertion, demand can exceed production: this is what makes glutamine a conditionally essential amino acid, and the reason why it was first studied in clinical nutrition, in patients, before becoming available as a supplement.
This physiological basis is solid. It does not say, by itself, that taking glutamine changes anything in a functioning intestine: that is what trials are for.
Permeability: what the meta-analysis says
The review included ten randomized placebo-controlled trials published between 1998 and 2014, totaling 352 participants, 216 in the glutamine groups and 212 in the control groups, with a mean age of 46.5 years and presenting various conditions. Glutamine was administered orally in all studies. Overall, supplementation did not significantly change intestinal permeability. Subgroup analysis showed a significant reduction in permeability at doses above 30 g per day, over periods of less than two weeks. The authors call for further investigations according to doses and populations.
Abbasi F, Haghighat Lari MM, Khosravi GR, Mansouri E, Payandeh N, Milajerdi A. Amino Acids 2024;56(1):60. DOI: 10.1007/s00726-024-03420-7
Two readings of this result, and both are correct. The first: in varied patients, at usual doses, glutamine does not change intestinal permeability on average. The second: at high doses, more than 30 g per day, and over a short period, it reduces it. This is consistent with its clinical history: glutamine has shown its effects on the barrier where demand is high and intake substantial, not in maintenance at low doses in someone who is well.
Post-infectious irritable bowel syndrome: the Gut trial
Adults who developed diarrhea-predominant irritable bowel syndrome with increased intestinal permeability following an intestinal infection were randomized between glutamine, 5 g three times daily, and placebo for eight weeks. The primary endpoint was a reduction of at least 50 points in the IBS-SS severity score. Fifty-four patients on glutamine and 52 on placebo completed the study. The primary endpoint was achieved in 43 patients, 79.6 percent, in the glutamine group and 3, 5.8 percent, in the placebo group. Glutamine also reduced all secondary endpoints: IBS-SS score at eight weeks, 181 versus 301; daily stool frequency, 2.9 versus 5.4; Bristol scale, 3.9 versus 6.5; intestinal permeability, 0.05 versus 0.11. Hyperpermeability was normalized in the glutamine group but not in the control group. Adverse effects were rare and similar in both groups; no serious effects were observed. The authors conclude that large randomized trials must now validate these results.
Zhou Q, Verne ML, Fields JZ, et al. Gut 2019;68(6):996-1002. DOI: 10.1136/gutjnl-2017-315136
This is a result rare in its magnitude, a fourteen-fold difference between glutamine and placebo, obtained by a university team from Tulane with public funding, and published in the most rigorous gastroenterology journal. It must be read exactly for what it is.
The patients had three combined characteristics : diarrhea-predominant irritable bowel, appearing after an intestinal infection, with measured hyperpermeability on the lactulose-mannitol test. The trial does not address irritable bowel syndrome in general, nor bloating, nor constipation, nor leaky gut as it is discussed on the internet. On this narrow ground, the effect is clear and permeability normalized; outside of this, the trial says nothing, and the meta-analysis above states that the average effect is null. It is also a single trial, of 106 patients, whose authors themselves call for replication.
"Leaky gut": what the expression covers
<<<19>>> Intestinal permeability perméabilité intestinale is a quantity that can be measured: two sugars, lactulose and mannitol, are consumed, and their ratio is measured in urine in the following hours. A high ratio indicates a more permeable barrier. It is observed in inflammatory bowel diseases, untreated celiac disease, after certain infections, in some intensive care patients, and after extreme exertion. It is on this measurement that the meta-analysis and the Gut trial focus. Gut.
The "leaky gut syndrome," on the internet, designates an independent diagnosis that would explain fatigue, joint pain, allergies, mood disorders, or weight gain. This syndrome, as a distinct clinical entity, is not recognized by gastroenterology societies, and no glutamine trial addresses it. Saying that a barrier can be more permeable in certain diseases is correct; inferring that unmeasured permeability explains general symptoms, and that a supplement repairs it, is not.
Digestive symptoms that persist deserve a diagnosis, not a label. Diarrhea appearing after gastroenteritis and persisting for months, precisely the presentation in the Gut trial Gut, should be discussed with a physician, who can rule out inflammatory disease, celiac disease, or persistent infection before discussing irritable bowel syndrome. Glutamine comes after this diagnosis, not in its place.
The athlete and immunity
Prolonged exercise and periods of intense training are accompanied by a decrease in plasma glutamine, which has been proposed as a cause of exercise-induced immune impairment and increased susceptibility to infections in athletes. However, several recent supplementation studies indicate that, although plasma concentration can be maintained constant during and after prolonged exercise, glutamine does not prevent post-exercise changes in several aspects of immune function. Glutamine is essential for lymphocyte proliferation, but its concentration does not decrease enough after exercise to compromise it. Acute doses of 20 to 30 g appear to have no adverse effects in healthy adults, and no damage has been reported in athletes consuming 28 g per day for 14 days. The reasons advanced for supplementation, immune support, glycogen synthesis, anticatabolic effect, have received little support from well-controlled studies in healthy, well-nourished humans.
Gleeson M. J Nutr 2008;138(10):2045S-2049S. DOI: 10.1093/jn/138.10.2045S
The reasoning was elegant, glutamine decreases after exercise, lymphocytes need it, therefore supplementing it protects; the trials did not confirm this, because the decrease is not profound enough to matter. What the review provides instead is a valuable piece of safety data: 20 to 30 g in a single dose, 28 g per day for two weeks, with no adverse effects in healthy adults. For muscle recovery, our dedicated article reviews the trials.
Dose, duration, and the safety limit
| Situation | Trial Dosage | Duration | Result |
|---|---|---|---|
| Post-infectious irritable bowel syndrome, measured hyperpermeability | 5 g three times daily, 15 g total | 8 weeks | 79.6% responders versus 5.8%, normalized permeability |
| Permeability in diverse patient populations | Standard doses | Variable | No overall effect |
| Permeability at high dose | Over 30 g per day | Less than 2 weeks | Significant reduction in subgroup |
| Athletes, immunity | 20 to 30 g | Single dose at 14 days | Well tolerated, no demonstrated immune effect |
| Critical care, multiorgan failure | High dose, intravenous and enteral | Upon admission | Increased mortality: contraindication in practice |
The REDOXS trial, published in 2013 in the New England Journal of Medicine, randomized 1,223 intensive care patients with multiorgan failure on mechanical ventilation across 40 units in Canada, the United States, and Europe, comparing high-dose intravenous and enteral glutamine, antioxidants, both, or placebo. Mortality at 28 days tended to be higher with glutamine, 32.4 versus 27.2 percent, and in-hospital mortality and mortality at six months were significantly higher. Glutamine had no effect on organ failures or infections.
This context, with patients in renal and hepatic failure receiving massive doses by infusion, bears no resemblance to a dietary supplement in a healthy individual. However, it establishes a rule without exception: in cases ofrenal or hepatic insufficiency, of serious illness orhospitalization, glutamine should be decided upon with the healthcare team, never on your own.
Heyland D, Muscedere J, Wischmeyer PE, et al. N Engl J Med 2013;368(16):1489-1497. DOI : 10.1056/NEJMoa1212722
Pure L-glutamine, additive-free, dosed to measure at 5 g in a glass of water. The format that allows you to find the fractioned doses from the trials, 5 g one to three times daily depending on your situation, and to adjust rather than undergo a fixed dose. For those whose condition has been assessed with a doctor.
View L-GlutamineDoes not treat any disease. Persistent digestive symptoms: diagnosis first. Kidney or liver insufficiency, serious illness: medical advice essential.
Choose what applies to you most: the answer appears just below.
This is exactly the trial population: an irritable colon with diarrhea that appeared after an infection. But the trial also required measured hyperpermeability and a diagnosis of irritable colon, thus excluding inflammatory disease, celiac disease, or persistent infection. Consult first; if diagnosis is confirmed, 5 g three times daily for eight weeks is the protocol that had 79.6% responders versus 5.8%, in a single trial whose authors ask to be replicated.
Leaky gut syndrome is not a recognized diagnosis, and no trial on glutamine covers bloating without identified cause. The meta-analysis shows null effect on permeability at usual doses in varied patients. Symptoms that persist deserve a consultation. For digestive comfort, our psyllium guide and our articles on probiotics cover actives that have trials on these symptoms.
The reference review is clear: glutamine maintains plasma levels after exercise but does not prevent immune changes, because the decrease is not deep enough to matter. No demonstrated effect on infections in athletes. Our article on zinc covers a nutrient that does have meta-analyses on the common cold.
This is the condition where glutamine has been most studied in clinical nutrition, and also where the REDOXS trial showed increased mortality at high doses in patients with organ failure. Kidney or liver insufficiency, active inflammatory disease, chemotherapy: the question of glutamine involves the care team, who knows your file. Not for self-medication.
This test provides guidance; it does not replace professional medical advice.
Frequently asked questions
Why is glutamine discussed for the intestine?
Because the cells that line the intestine, enterocytes, use glutamine as their primary fuel, before glucose. It is the most abundant amino acid in blood and muscles, and the body produces it itself; but in situations of metabolic stress, infection, surgery, prolonged effort, demand can exceed production, making it a conditionally essential amino acid. It is on this basis that glutamine has been studied for intestinal barrier function.
Does glutamine repair intestinal permeability?
Not in a general way, and it's a 2024 meta-analysis that says so. Published in Amino Acids, it combined ten randomized trials versus placebo, from 1998 to 2014, 352 participants, all with various conditions, and measured permeability before and after oral glutamine. Overall, no significant effect. In subgroup analysis, a significant reduction in permeability at doses above 30 g daily for less than two weeks. The authors' conclusion: glutamine acts on permeability at high dose and over short duration, and further trials are needed according to doses and populations.
What does the Gut trial show on irritable colon?
It is the most striking trial on glutamine and the intestine. Published in Gut In 2019 by Tulane University, it randomized adults who developed diarrhea-predominant irritable bowel syndrome following an intestinal infection, with increased intestinal permeability measured by the lactulose-mannitol test. Eight weeks at 5 g of glutamine three times daily or placebo. The primary endpoint, a decrease of at least 50 points in the severity score, was achieved in 79.6% of patients on glutamine versus 5.8% on placebo. Stool frequency decreased from 5.4 to 2.9 per day, permeability normalized, and no serious adverse effects were observed. The authors call for large trials to confirm.
Does this apply to everyone?
No, and that's the essential point. The trial in Gut focuses on a very specific population: irritable bowel syndrome that appeared after an infection, with measured hyperpermeability. It does not cover irritable bowel syndrome in general, nor bloating, nor leaky gut as discussed on the internet. The meta-analysis also shows that in diverse patient populations, the average effect on permeability is null at usual doses. Glutamine therefore has a documented, narrow and clear indication, and not general efficacy for the intestine.
What is leaky gut, really?
Intestinal permeability is a measurable parameter: two sugars, lactulose and mannitol, are ingested and their ratio is measured in urine. A high ratio indicates a more permeable barrier, which is observed in certain inflammatory diseases, celiac disease, after certain infections or extreme exertion. Conversely, leaky gut syndrome as an autonomous diagnosis, cause of fatigue, joint pain or allergies, is not a recognized medical entity. Trials on glutamine focus on the measured parameter, not the syndrome.
Does glutamine protect the athlete's immunity?
Not according to the reference review. Published in the Journal of Nutrition by Michael Gleeson, from Loughborough University, it recalls that prolonged exercise decreases plasma glutamine, but that supplementation trials, although they maintain this level, do not prevent post-exercise immune changes, because the decrease is not sufficient to limit lymphocyte proliferation. It notes that 20 to 30 g in a single dose and 28 g per day for 14 days were well tolerated, and concludes that the reasons given for supplementation, immunity, glycogen, anticatabolic effect, received little support from well-controlled trials in healthy and well-nourished adults.
Is glutamine safe?
In healthy adults, at trial doses, yes: up to 30 g per day with no notable adverse effects, and no serious effects in the Gut trial at 15 g per day for eight weeks. However, there is a clear limit, set by the REDOXS trial published in the New England Journal of Medicine : in 1,223 intensive care patients with multiorgan failure, high-dose glutamine given intravenously and enterally was associated with increased hospital and six-month mortality. This is a context unrelated to a dietary supplement in a healthy person, but it sets the rule: in case of renal or hepatic insufficiency, serious illness or hospitalization, glutamine should be decided with a doctor, never on your own.
What dose and for how long?
The Gut trial used 5 g three times daily, or 15 g, for eight weeks. The meta-analysis on permeability finds an effect only above 30 g per day for less than two weeks, in patients. The amounts that showed something are therefore in the range of 15 to 30 g per day, in multiple doses, and over weeks. A powder is dosed with a 5 g measure, which allows adjustment. And any persistent abdominal pain, any bleeding, any weight loss or diarrhea that persists should be discussed with a doctor before any supplement.
What to remember about glutamine and the intestine?
That glutamine is the fuel for intestinal cells, and that's the basis of its study. That a meta-analysis finds no general effect on permeability, except at high doses. That a Gut trial shows a clear effect, 79.6 versus 5.8% responders, in very specific patients: post-infectious irritable bowel syndrome with measured hyperpermeability. That leaky gut as a syndrome is not a recognized diagnosis. That athlete immunity has no solid evidence. And that glutamine is safe in healthy adults, but should be decided with a doctor in case of serious illness.
Glossary
- Enterocytes
- Absorbing cells of the small intestine wall, renewed in a few days, for which glutamine is the primary fuel.
- Conditionally essential amino acid
- Amino acid that the body produces normally, but whose demand can exceed production in situations of metabolic stress.
- Intestinal permeability
- Capacity of the wall to allow molecules to pass between its cells; measured by the urinary lactulose-to-mannitol ratio.
- Lactulose-mannitol test
- Measure of permeability: two sugars ingested, one absorbed between cells, the other through them; their urinary ratio provides information about the barrier.
- Post-infectious IBS-D
- Diarrhea-predominant irritable bowel syndrome that appeared after a digestive infection; the population of the Gut trial.
- IBS-SS
- Irritable bowel syndrome severity score; a decrease of 50 points is considered clinically significant.
- REDOXS
- A 2013 randomized trial in 1,223 intensive care patients that demonstrated increased mortality with high-dose glutamine in multi-organ failure.
Sources
The studies cited below were identified via PubMed.
- Abbasi F, Haghighat Lari MM, Khosravi GR, Mansouri E, Payandeh N, Milajerdi A. Systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on intestinal permeability in adults. Amino Acids, 2024;56(1):60. DOI
- Zhou Q, Verne ML, Fields JZ, et al. Randomized placebo-controlled trial of dietary glutamine in post-infectious irritable bowel syndrome. Gut, 2019;68(6):996-1002. DOI
- Gleeson M. Dosage and efficacy of glutamine supplementation in exercise and sports training in humans. Journal of Nutrition, 2008;138(10):2045S-2049S. DOI
- Heyland D, Muscedere J, Wischmeyer PE, et al. Randomized trial of glutamine and antioxidants in critically ill patients. New England Journal of Medicine, 2013;368(16):1489-1497. DOI


